Loading clinical trials...
Loading clinical trials...
The purpose of this phase 1b/2 study is to evaluate the safety, tolerability, and antitumor activity of HDM2005 in combination with standard of care in participants with diffuse large B-cell lymphoma....
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
NCT07260812 · Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL)
NCT05366569 · Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), and more
NCT04792489 · Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, and more
NCT04772989 · Advanced Solid Tumor, Non Small Cell Lung Cancer (NSCLC), and more
NCT06748521 · Diffuse Large B Cell Lymphoma (DLBCL)
Peking University Cancer Hospital
Beijing, Beijing Municipality
Fujian Cancer Hospital
Fuzhou, Fujian
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions